Donanemab: A Turning Point in the Battle Against Alzheimer’s Disease

🧠 A global trial confirmed that donanemab, an antibody medicine, can slow cognitive decline.

How Does Donanemab Work?

The drug works by removing clumps of amyloid protein from the brain that are believed to cause Alzheimer’s disease.

The Results

The trial was conducted on 257 patients with early symptoms of Alzheimer’s disease and the results showed that the drug slowed cognitive decline by 32% compared to a placebo.

A Significant Breakthrough

This is a significant breakthrough in the fight against Alzheimer’s disease and could potentially help millions of people worldwide.